Holen Sie sich die Stockscreener-App
19.52
2.25%
0.43
Handel nachbörslich:
19.52
Schlusskurs vom Vortag:
$19.09
Offen:
$19.1
24-Stunden-Volumen:
106.20K
Relative Volume:
1.10
Marktkapitalisierung:
$652.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-3.8836
EPS:
-5.0262
Netto-Cashflow:
-
1W Leistung:
-12.31%
1M Leistung:
+3.94%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$18.88
$21.07
1-Wochen-Bereich:
$18.56
$22.80
52-Wochen-Spanne:
$17.06
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Firmenname
Spyglass Pharma Inc
Sektor
Branche
Telefon
949-284-6904
Adresse
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
19.52 | 638.24M | 0 | 0 | 0 | -5.0262 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-03 | Eingeleitet | Citigroup | Buy |
| 2026-03-03 | Eingeleitet | Jefferies | Buy |
| 2026-03-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-03 | Eingeleitet | Stifel | Buy |
Spyglass Pharma Inc Aktie (SGP) Neueste Nachrichten
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Value Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Value Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS:SGP) added to Russell Microcap Growth Benchmark Index - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 2000 Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell 3000E Growth Benchmark - marketscreener.com
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to Russell Microcap Index - marketscreener.com
SGP Forecast — Price Target — Prediction for 2027 - TradingView
Transcript : SpyGlass Pharma, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
SpyGlass Pharma, Inc. Actuals & Estimates (NASDAQ:SGP) - TradingView
Price to sales forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Enterprise value to revenue forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Price to book forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Price to earnings forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Enterprise value to EBIT forward of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
Spyglass Pharma (SGP) Short Interest & Short Float | Updated Jun 2026 $SGP - MarketBeat
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
SpyGlass Pharma Inc. Q1 2026 Earnings: Wider-Than-Expected Loss Fails to Dampen Investor OptimismRevenue Miss Report - dars.gov.et
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P Global BMI Index - marketscreener.com
SpyGlass Pharma Ord shs (Proposed) (SGP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SpyGlass Taps Shannon Treviño as General Counsel - Orange County Business Journal
SpyGlass Pharma appoints Shannon Treviño as general counsel to support Phase 3 trials and commercialization plans. - Pluang
SpyGlass Pharma appoints Shannon Treviño as general counsel By Investing.com - Investing.com Nigeria
SpyGlass Pharma, Inc. Announces Appointment of Shannon Treviño to General Counsel - marketscreener.com
SpyGlass Pharma appoints Shannon Treviño as general counsel - Investing.com
SpyGlass Pharma Appoints Shannon Treviño as General Counsel - GlobeNewswire
SpyGlass Pharma Inc. Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesAnnual Report - dars.gov.et
Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP - MarketBeat
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing - VisionMonday.com
SpyGlass Pharma appoints Mike Pinder as VP of marketing By Investing.com - Investing.com South Africa
SpyGlass Pharma appoints Mike Pinder as VP of marketing - Investing.com
SpyGlass Pharma (SGP) Slides 2.29% as Stock Approaches Critical Support at $17.0Liquidity Sweep - dars.gov.et
SGP Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesCapex Guidance - dars.gov.et
SGPSpyGlass Pharma Inc Stock Price and Quote - Finviz
SpyGlass Pharma to Participate in Upcoming Investor Conferences - Sahm
SpyGlass Pharma: New add-on CPT code supports BIM-IOL System - Eyes On Eyecare
SpyGlass Secures Billing Code for IOL Platform - Orange County Business Journal
Spyglass Pharma IncBIM-Iol System Phase 3 Trial Enrollment Expected To Complete In 2027 - TradingView
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System - GlobeNewswire
SpyGlass Pharma (SGP) Q1 2026 Earnings Miss by Significant: Key TakeawaysBuyback Authorization - newser.com
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance By Investing.com - Investing.com South Africa
SpyGlass Pharma posts Q1 loss as Phase 3 trials advance - Investing.com India
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Sahm
Number of shareholders of SpyGlass Pharma, Inc. – NASDAQ:SGP - TradingView
SpyGlass Pharma (SGP) boosts cash to $251M after IPO while losses widen - Stock Titan
Finanzdaten der Spyglass Pharma Inc-Aktie (SGP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyglass Pharma Inc-Aktie (SGP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Behbahani Ali | Director |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Florence Anthony A. Jr. | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| BASKETT FOREST | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| New Enterprise Associates 17, | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Yang Rick | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Makhzoumi Mohamad | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| SANDELL SCOTT D | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Chang Carmen | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Walker Paul Edward | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
| Mathers Edward T | 10% Owner |
Feb 09 '26 |
Buy |
16.00 |
937,500 |
15,000,000 |
6,035,038 |
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):